{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:56:51Z","timestamp":1781614611943,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["162063"],"award-info":[{"award-number":["162063"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Few studies have systematically examined the barriers and facilitators to buprenorphine uptake, despite increasing opioid-related harms and guideline recommendations for use. The aim of the study was to use behaviour change frameworks to investigate barriers and facilitators to buprenorphine access and use from diverse perspectives in Ontario, Canada.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted semi-structured face-to-face or telephone interviews with Ontarians including: people with living\/lived expertise of opioid use (including family members), healthcare professionals, and organizational and system-level representatives. We used purposive sampling via existing professional networks to recruit participants with diverse experiences. The Theoretical Domains Framework (TDF) guided the data collection tool and analysis. Interviews were recorded, transcribed, coded, and underwent thematic analysis involving three study team members.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We interviewed 28 participants between September 2019 and January 2020. Three predominant TDF domains were identified across all 4 levels: (1) environmental context\/resources; (2) beliefs about consequences; (3) social influences. Key cross-cutting themes included access to comprehensive care, medication and treatment characteristics, confidence and experiences with buprenorphine, as well as supportive relationships and stigma\/discrimination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Multi-level barriers to optimal buprenorphine implementation continue in the face of the drug toxicity crisis. To counter the identified barriers and enhance facilitators, there is need for mentorship models of support for prescribing, flexibility in buprenorphine treatment requirements, better recognition of mental health and the social determinants of health in buprenorphine treatment, and comprehensive and integrated systems of care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-025-00610-w","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:58:05Z","timestamp":1761044285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-level barriers and facilitators to buprenorphine use in Ontario, Canada: a qualitative study using the theoretical domains framework"],"prefix":"10.1186","volume":"20","author":[{"given":"Pamela","family":"Leece","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Triti","family":"Khorasheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Zerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Corace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Strike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Bayomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Holowaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Crichlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon E.","family":"Straus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"610_CR1","unstructured":"Federal, provincial, and territorial special advisory committee on the epidemic of opioid overdoses. Opioid- and stimulant-related harms in Canada (September 2023) [Internet]. Ottawa: Public Health Agency of Canada; 2023 Sep [cited 2023 Dec 4]. Available from: https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants\/"},{"key":"610_CR2","unstructured":"Health Canada. The Canadian drugs\u2009+\u2009substances strategy: the Government of Canada\u2019s approach to substance use related harms and the overdose crisis [Internet]. Ottawa, ON: Health Canada; 2023 Oct [cited 2023 Dec 10] p. 26. Available from: https:\/\/www.canada.ca\/content\/dam\/hc-sc\/documents\/services\/publications\/healthy-living\/canadian-drugs-substances-strategy-approach-related-harms-overdose-crisis\/cdss-report-eng.pdf"},{"issue":"9","key":"610_CR3","doi-asserted-by":"publisher","first-page":"E247","DOI":"10.1503\/cmaj.170958","volume":"190","author":"J Bruneau","year":"2018","unstructured":"Bruneau J, Ahamad K, Goyer M\u00c8, Poulin G, Selby P, Fischer B, et al. Management of opioid use disorders: a national clinical practice guideline. Can Med Assoc J. 2018;190(9):E247\u201357.","journal-title":"Can Med Assoc J"},{"issue":"2","key":"610_CR4","first-page":"CD002025","volume":"2","author":"L Gowing","year":"2017","unstructured":"Gowing L, Ali R, White JM, Mbewe D. Buprenorphine for managing opioid withdrawal. Cochrane Database Syst Rev. 2017;2(2):CD002025.","journal-title":"Cochrane Database Syst Rev"},{"key":"610_CR5","unstructured":"Ontario opioid indicator tool [Internet]. ODPRN. 2022 Aug [cited 2023 Dec 10]. Available from: https:\/\/odprn.ca\/ontario-opioid-drug-observatory\/ontario-prescription-opioid-tool\/"},{"issue":"4","key":"610_CR6","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/add.16096","volume":"118","author":"LA Paul","year":"2023","unstructured":"Paul LA, Bayoumi AM, Chen C, Kocovska E, Smith BT, Raboud JM, et al. Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population\u2010based retrospective cohort study. Addiction. 2023;118(4):686\u201397.","journal-title":"Addiction"},{"issue":"14","key":"610_CR7","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1080\/10826084.2019.1653324","volume":"54","author":"B Tofighi","year":"2019","unstructured":"Tofighi B, Williams AR, Chemi C, Suhail-Sindhu S, Dickson V, Lee JD. Patient barriers and facilitators to medications for opioid use disorder in primary care. Subst Use Misuse. 2019;54(14):2409\u201319.","journal-title":"Subst Use Misuse"},{"issue":"5","key":"610_CR8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1080\/02791072.2014.921743","volume":"46","author":"C Teruya","year":"2014","unstructured":"Teruya C, Schwartz RP, Mitchell SG, Hasson AL, Thomas C, Buoncristiani SH, et al. Patient perspectives on buprenorphine\/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. J Psychoact Drugs. 2014;46(5):412\u201326.","journal-title":"J Psychoact Drugs"},{"key":"610_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.drugalcdep.2018.02.018","volume":"187","author":"AE Muller","year":"2018","unstructured":"Muller AE, Bj\u00f8rnestad R, Clausen T. Dissatisfaction with opioid maintenance treatment partly explains reported side effects of medications. Drug Alcohol Depend. 2018;187:22\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"610_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.5055\/jom.2013.0152","volume":"9","author":"NL Sohler","year":"2013","unstructured":"Sohler NL, Weiss L, Egan JE, L\u00f3pez CM, Favaro J, Cordero R, et al. Consumer attitudes about opioid addiction treatment: a focus group study in New York City. J Opioid Manag. 2013;9(2):111\u20139.","journal-title":"J Opioid Manag"},{"issue":"1","key":"610_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13011-016-0085-y","volume":"12","author":"VM Hewell","year":"2017","unstructured":"Hewell VM, Vasquez AR, Rivkin ID. Systemic and individual factors in the buprenorphine treatment-seeking process: a qualitative study. Subst Abuse Treat Prev Policy. 2017;12(1):3.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"610_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.drugalcdep.2018.03.033","volume":"188","author":"P Vanderkam","year":"2018","unstructured":"Vanderkam P, Gagey S, Ingrand P, Perault-Pochat MC, Brabant Y, Blanchard C, et al. Are patients\u2019 pejorative representations of buprenorphine associated with their level of addiction and of misuse? Drug Alcohol Depend. 2018;188:10\u20135.","journal-title":"Drug Alcohol Depend"},{"key":"610_CR13","unstructured":"Canadian Association of People Who Use Drugs. Hear us, see us, respect us: respecting the expertise of people who use drugs [Internet]. Canadian association of people who use drugs. 2021. Available from: https:\/\/zenodo.org\/records\/5514066#.Y2_FOnbMJPa"},{"key":"610_CR14","unstructured":"Canadian HIVAIDS, Legal Network. \u201cNothing about us without us\u201d: greater, meaningful involvement of people who use illegal drugs: a public health, ethical, and human rights imperative [Internet]. Canada: Canadian HIV\/AIDS legal network; 2006 Mar [cited 2025 Mar 27]. Available from: http:\/\/www.hivlegalnetwork.ca\/site\/wp-content\/uploads\/2013\/04\/Greater+Involvement+-+Bklt+-+Drug+Policy+-+ENG.pdf"},{"issue":"2","key":"610_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1037\/a0022776","volume":"25","author":"AJ Gordon","year":"2011","unstructured":"Gordon AJ, Kavanagh G, Krumm M, Ramgopal R, Paidisetty S, Aghevli M, et al. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychol Addict Behav. 2011;25(2):215\u201324.","journal-title":"Psychol Addict Behav"},{"key":"610_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2016.10.005","volume":"74","author":"A Kermack","year":"2017","unstructured":"Kermack A, Flannery M, Tofighi B, McNeely J, Lee JD. Buprenorphine prescribing practice trends and attitudes among New York providers. J Subst Abuse Treat. 2017;74:1\u20136.","journal-title":"J Subst Abuse Treat"},{"key":"610_CR17","first-page":"3019","volume":"15","author":"JR DeFlavio","year":"2015","unstructured":"DeFlavio JR, Rolin SA, Nordstrom BR, Kazal LA. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health. 2015;15:3019.","journal-title":"Rural Remote Health"},{"key":"610_CR18","first-page":"117822181769924","volume":"11","author":"TV Parran","year":"2017","unstructured":"Parran TV, Muller JZ, Chernyak E, Adelman C, Delos Reyes CM, Rowland D, et al. Access to and payment for office-based buprenorphine treatment in Ohio. Subst Abuse Res Treat. 2017;11:117822181769924.","journal-title":"Subst Abuse Res Treat"},{"issue":"4","key":"610_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/jamapsychiatry.2013.4450","volume":"71","author":"SC Sigmon","year":"2014","unstructured":"Sigmon SC. Access to treatment for opioid dependence in rural America: challenges and future directions. JAMA Psychiatry. 2014;71(4):359.","journal-title":"JAMA Psychiatry"},{"issue":"2\u20133","key":"610_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/10550887.2015.1059113","volume":"34","author":"MW Parrino","year":"2015","unstructured":"Parrino MW, Maremmani AGI, Samuels PN, Maremmani I. Challenges and opportunities for the use of medications to treat opioid addiction in the United States and other nations of the world. J Addict Dis. 2015;34(2\u20133):255\u201362.","journal-title":"J Addict Dis"},{"issue":"1","key":"610_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1748-5908-7-37","volume":"7","author":"J Cane","year":"2012","unstructured":"Cane J, O\u2019Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement Sci. 2012;7(1):37.","journal-title":"Implement Sci"},{"key":"610_CR22","volume-title":"The behavior change wheel: a guide to designing interventions","author":"S Michie","year":"2014","unstructured":"Michie S, Atkins L, West R. The behavior change wheel: a guide to designing interventions. Great Britain: Silverback Publishing; 2014."},{"issue":"12","key":"610_CR23","doi-asserted-by":"publisher","first-page":"e032285","DOI":"10.1136\/bmjopen-2019-032285","volume":"9","author":"P Leece","year":"2019","unstructured":"Leece P, Khorasheh T, Corace K, Strike C, Bayoumi AM, Taha S, et al. Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review. BMJ Open. 2019;9(12):e032285.","journal-title":"BMJ Open"},{"issue":"1","key":"610_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13012-016-0399-1","volume":"11","author":"AR Gagliardi","year":"2015","unstructured":"Gagliardi AR, Berta W, Kothari A, Boyko J, Urquhart R. Integrated knowledge translation (IKT) in health care: a scoping review. Implement Sci. 2015;11(1):38.","journal-title":"Implement Sci"},{"issue":"9","key":"610_CR25","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","volume":"89","author":"BC O\u2019Brien","year":"2014","unstructured":"O\u2019Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245\u201351.","journal-title":"Acad Med"},{"key":"610_CR26","doi-asserted-by":"publisher","first-page":"107672","DOI":"10.1016\/j.drugalcdep.2019.107672","volume":"205","author":"SA Weicker","year":"2019","unstructured":"Weicker SA, Hayashi K, Grant C, Milloy MJ, Wood E, Kerr T. Willingness to take buprenorphine\/naloxone among people who use opioids in Vancouver, Canada. Drug Alcohol Depend. 2019;205:107672.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"610_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/JXX.0000000000000811","volume":"35","author":"C Speight","year":"2023","unstructured":"Speight C, Caiola C, Tyndall DE, Scott ES. Barriers and facilitators to nurse practitioner buprenorphine prescribing for opioid use disorder in primary care settings. J Am Assoc Nurse Pract. 2023;35(2):112\u201321.","journal-title":"J Am Assoc Nurse Pract"},{"issue":"1","key":"610_CR28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12913-024-10648-2","volume":"24","author":"AN Nyaku","year":"2024","unstructured":"Nyaku AN, Zerbo EA, Chen C, Milano N, Johnston B, Chadwick R, et al. A survey of barriers and facilitators to the adoption of buprenorphine prescribing after implementation of a New Jersey-wide incentivized DATA-2000 waiver training program. BMC Health Serv Res. 2024;24(1):179.","journal-title":"BMC Health Serv Res"},{"issue":"12","key":"610_CR29","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1080\/10826084.2022.2112226","volume":"57","author":"S Bapat","year":"2022","unstructured":"Bapat S, Washburn M, Tata V, Fleming M, Abughosh SM, Essien EJ, et al. Barriers and facilitators to DATA waivered providers prescribing buprenorphine: a qualitative analysis applying the theory of planned behavior. Subst Use Misuse. 2022;57(12):1761\u201371.","journal-title":"Subst Use Misuse"},{"issue":"14","key":"610_CR30","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1001\/jama.286.14.1715","volume":"286","author":"C Weisner","year":"2001","unstructured":"Weisner C, Mertens J, Parthasarathy S, Moore C, Lu Y. Integrating primary medical care with addiction treatment: a randomized controlled trial. JAMA. 2001;286(14):1715.","journal-title":"JAMA"},{"key":"610_CR31","doi-asserted-by":"publisher","first-page":"108633","DOI":"10.1016\/j.jsat.2021.108633","volume":"132","author":"N Beharie","year":"2022","unstructured":"Beharie N, Kaplan-Dobbs M, Urmanche A, Paone D, Harocopos A. I didn\u2019t feel like a number: the impact of nurse care managers on the provision of buprenorphine treatment in primary care settings. J Subst Abuse Treat. 2022;132:108633.","journal-title":"J Subst Abuse Treat"},{"key":"610_CR32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/archinternmed.2010.541","volume":"171","author":"DP Alford","year":"2011","unstructured":"Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171:425\u201331.","journal-title":"Arch Intern Med"},{"issue":"10","key":"610_CR33","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1037\/ccp0000410","volume":"87","author":"DE Logan","year":"2019","unstructured":"Logan DE, Lavoie AM, Zwick WR, Kunz K, Bumgardner MA, Molina Y. Integrating addiction medicine into rural primary care: strategies and initial outcomes. J Consult Clin Psychol. 2019;87(10):952\u201361.","journal-title":"J Consult Clin Psychol"},{"key":"610_CR34","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jsat.2009.05.003","volume":"37","author":"JM Soeffing","year":"2009","unstructured":"Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat. 2009;37:426\u201330.","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"610_CR35","doi-asserted-by":"publisher","first-page":"e1003631","DOI":"10.1371\/journal.pmed.1003631","volume":"18","author":"T Gomes","year":"2021","unstructured":"Gomes T, Campbell TJ, Martins D, Paterson JM, Robertson L, Juurlink DN, et al. Inequities in access to primary care among opioid recipients in Ontario, Canada: a population-based cohort study. Z Song editor. PLOS Med. 2021;18(6):e1003631.","journal-title":"PLOS Med"},{"issue":"S3","key":"610_CR36","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s11606-020-06257-4","volume":"35","author":"K Mackey","year":"2020","unstructured":"Mackey K, Veazie S, Anderson J, Bourne D, Peterson K. Barriers and facilitators to the use of medications for opioid use disorder: a rapid review. J Gen Intern Med. 2020;35(S3):954\u201363.","journal-title":"J Gen Intern Med"},{"key":"610_CR37","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.drugpo.2019.06.019","volume":"71","author":"K McLean","year":"2019","unstructured":"McLean K, Kavanaugh PR. They\u2019re making it so hard for people to get help: motivations for non-prescribed buprenorphine use in a time of treatment expansion. Int J Drug Policy. 2019;71:118\u201324.","journal-title":"Int J Drug Policy"},{"key":"610_CR38","unstructured":"Lam V, Sankey C, Wyman J, Zhang M. COVID-19: opioid agonist treatment guidance. Toronto, ON: centre for addiction and mental health (CAMH), Mentoring, Education, and clinical tools for addiction primary care hospital integration. META-PHI), and the Ontario Medical Assocation (OMS); 2020 Mar."},{"key":"610_CR39","doi-asserted-by":"publisher","first-page":"100135","DOI":"10.1016\/j.dadr.2023.100135","volume":"6","author":"PJ Roy","year":"2023","unstructured":"Roy PJ, Callaway Kim K, Suda K, Luo J, Wang X, Olejniczak D, et al. Impact of COVID-19-related regulatory changes on nationwide access to buprenorphine: an interrupted time series design. Drug Alcohol Depend Rep. 2023;6:100135.","journal-title":"Drug Alcohol Depend Rep"},{"key":"610_CR40","doi-asserted-by":"publisher","first-page":"100055","DOI":"10.1016\/j.dadr.2022.100055","volume":"3","author":"KM Ward","year":"2022","unstructured":"Ward KM, Scheim A, Wang J, Cocchiaro B, Singley K, Roth AM. Impact of reduced restrictions on buprenorphine prescribing during COVID-19 among patients in a community-based treatment program. Drug Alcohol Depend Rep. 2022;3:100055.","journal-title":"Drug Alcohol Depend Rep"},{"key":"610_CR41","doi-asserted-by":"publisher","first-page":"103573","DOI":"10.1016\/j.drugpo.2021.103573","volume":"102","author":"K Corace","year":"2022","unstructured":"Corace K, Suschinsky K, Wyman J, Leece P, Cragg S, Konefal S, et al. Evaluating how has care been affected by the Ontario COVID-19 opioid agonist treatment guidance: patients\u2019 and prescribers\u2019 experiences with changes in unsupervised dosing. Int J Drug Policy. 2022;102:103573.","journal-title":"Int J Drug Policy"},{"key":"610_CR42","doi-asserted-by":"publisher","first-page":"103680","DOI":"10.1016\/j.drugpo.2022.103680","volume":"104","author":"Z Bouck","year":"2022","unstructured":"Bouck Z, Scheim AI, Gomes T, Ling V, Caudarella A, Werb D. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions. Int J Drug Policy. 2022;104:103680.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"610_CR43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12954-021-00467-7","volume":"18","author":"R Lennox","year":"2021","unstructured":"Lennox R, Lamarche L, O\u2019Shea T. Peer support workers as a bridge: a qualitative study exploring the role of peer support workers in the care of people who use drugs during and after hospitalization. Harm Reduct J. 2021;18(1):19.","journal-title":"Harm Reduct J"},{"issue":"1","key":"610_CR44","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/jrh.12328","volume":"35","author":"CHA Andrilla","year":"2019","unstructured":"Andrilla CHA, Moore TE, Patterson DG. Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: recommendations from rural physicians. J Rural Health. 2019;35(1):113\u201321.","journal-title":"J Rural Health"},{"issue":"1","key":"610_CR45","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12875-019-1047-z","volume":"20","author":"DL Louie","year":"2019","unstructured":"Louie DL, Assefa MT, McGovern MP. Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review. BMC Fam Pract. 2019;20(1):157.","journal-title":"BMC Fam Pract"},{"key":"610_CR46","doi-asserted-by":"publisher","first-page":"209270","DOI":"10.1016\/j.josat.2023.209270","volume":"159","author":"K McLean","year":"2024","unstructured":"McLean K, Murphy J, Kruis N. I think we\u2019re getting better but we\u2019re still not there: provider-based stigma and perceived barriers to care for people who use opioids (PWUO). J Subst Use Addict Treat. 2024;159:209270.","journal-title":"J Subst Use Addict Treat"},{"key":"610_CR47","doi-asserted-by":"publisher","first-page":"S230","DOI":"10.1016\/j.amepre.2017.12.022","volume":"54","author":"RL Haffajee","year":"2018","unstructured":"Haffajee RL, Bohnert ASB, Lagisetty PA. Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med. 2018;54:S230\u201342.","journal-title":"Am J Prev Med"},{"key":"610_CR48","doi-asserted-by":"crossref","unstructured":"Atkins J, Legreid Dopp A, Boone Temaner E. Combatting the stigma of addiction\u2014the need for a comprehensive health system approach. NAM Perspect [Internet]. 2020 Nov 9 [cited 2025 Mar 27]; Available from: https:\/\/nam.edu\/combatting-the-stigma-of-addiction-the-need-for-a-comprehensive-health-system-approach","DOI":"10.31478\/202011d"},{"key":"610_CR49","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.drugpo.2019.10.005","volume":"74","author":"MD McCradden","year":"2019","unstructured":"McCradden MD, Vasileva D, Orchanian-Cheff A, Buchman DZ. Ambiguous identities of drugs and people: a scoping review of opioid-related stigma. Int J Drug Policy. 2019;74:205\u201315.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"610_CR50","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/ADM.0000000000001202","volume":"17","author":"MB Weimer","year":"2023","unstructured":"Weimer MB, Herring AA, Kawasaki SS, Meyer M, Kleykamp BA, Ramsey KS. ASAM clinical considerations: buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids. J Addict Med. 2023;17(6):632\u20139.","journal-title":"J Addict Med"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00610-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00610-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00610-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:18:08Z","timestamp":1781612288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13722-025-00610-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["610"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00610-w","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol (2019\u2009\u2212\u2009031.01) was approved by the Ethics Review Board at Public Health Ontario on August 14, 2019.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Participants provided verbal consent to participate in the study, which included sharing and publishing the study results. This manuscript does not include identifiable data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}